KTRAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients...

Stats
本日の出来高	5.09M
平均出来高	14.92M
時価総額	8.48M
EPS	$0 ( 2024-02-13 )
次の収益日	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-30	Johnson Laura L.	Buy	8 500	Options (Right to Buy)
2023-08-30	Favorito Tamara A	Buy	8 500	Options (Right to Buy)
2023-08-30	Hoffman Robert E.	Buy	23 142	Options (Right to Buy)
2023-08-30	Toth Robert Joseph Jr	Buy	8 500	Options (Right to Buy)
2023-08-30	Brown Dennis M	Buy	10 175	Options (Right to Buy)

INSIDER POWER
100.00
Last 96 transactions
Buy: 12 848 509 \| Sell: 15 566

ボリューム相関

長: 0.28 (neutral)

短: 0.00 (neutral)

Signal:(74.36) Neutral

Kintara Therapeutics, 相関

10 最も正の相関
CRON	0.925
EVLO	0.918
RPTX	0.904
SLNG	0.901
CFRX	0.899
DRUG	0.898
LVTX	0.897
JAGX	0.895
REYN	0.894
KNSA	0.894

10 最も負の相関
CSLM	-0.923
HERA	-0.911
TBSAU	-0.91
CITE	-0.909
PPYA	-0.906
HERAU	-0.903
FRON	-0.903
ABGI	-0.903
FTAA	-0.901
BYNOU	-0.901

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kintara Therapeutics, 相関 - 通貨/商品

0.00
( neutral )

Kintara Therapeutics, 財務諸表

Annual	2023
収益:	$0
総利益:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2023
収益:	$0
総利益:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2022
収益:	$0
総利益:	$-60 000.00 (0.00 %)
EPS:	$-23.22

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-73.97

Financial Reports:

No articles found.

Kintara Therapeutics,

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.